MedTrace Logo

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

NCT07242300 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2025-11-21

No results posted yet for this study

Summary

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

Conditions

  • Upper Limb Spasticity (ULS)

Interventions

DRUG

Recombinant Botulinum Toxin Type A for injection

Recombinant Botulinum Toxin Type A for injection

DRUG

Placebo

Placebo will be administered in double-blind fashion during treatment cycle 1 only

Sponsors & Collaborators

  • JHM BioPharma (Tonghua) Co. , Ltd.

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-12-31
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07242300 on ClinicalTrials.gov